TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07502664: Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Sponsor: Ray Therapeutics, Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 25 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07502664 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07502664 Rescue Dossier →